## SRPT: Sarepta Therapeutics, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.0% below STRENGTH zone (3.0-6.0%); PEG 159.25 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($19.36)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bearish (Bullish: 0, Bearish: 1)

**1. Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Investors to Inquire about Securities Investigation**
- Source: KLAS 8 News Now | 20251222T160827 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased Sarepta Therapeutics, Inc. (NASDAQ:SRPT) securities. This investigation follows a significant stock price drop after Sarepta disclosed that its late-stage ESSENCE trial for two gene therapies did not meet statistical significance on its primary endpoint. The firm encourages affected Sarepta investors to contact them for more information and to assist in the investigation.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Wedbush | $32 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Wedbush | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 4 ($0.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Blackrock Inc.: 12.6% (+8.9%)
- Vanguard Group Inc: 10.3% (+18.1%)
- State Street Corpora: 5.1% (+13.0%)
- Erste Asset Manageme: 2.6% (+65.7%)
- Renaissance Technolo: 2.5% (+324.4%)

### Key Risks

1. Valuation stretched: PEG 159.2x requires aggressive growth execution.
2. High short interest (21.6%, 3.4 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 29.6% below SMA200.
4. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- Momentum building: MRS_10 improving +1.9% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 159.25 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (3.0x). Revenue declining -25% YoY, concerning. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.3B |
| Beta | 0.53 |
| 52W Range | $10.42 - $129.84 |
| Short Interest | 21.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 159.25 |
| Forward P/E | 7.9 |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from -0.9% to 1.0% (+1.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.0pp (needs >3.0% for momentum thesis). MRS_5 at 2.4% confirms short-term momentum alignment. Below SMA200 (0.70x), long-term trend not supportive. RSI neutral at 56. OFD pattern: +MUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.98% (CS: 84) | Neutral |
| RSI_14 | 55.9 | Neutral |
| MACD Histogram | -0.04 | Bearish |
| vs SMA20 | 1.028x | Above |
| vs SMA50 | 1.059x | Above |
| vs SMA200 | 0.704x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $22.00
- **Stop Loss:** $19.36 (12.0% risk)
- **Target:** $24.64 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 454
- **Position Value:** $9,988.00
- **Portfolio %:** 9.99%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-25 (Est: $-0.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.37 | $-0.13 | +65.0% |
| 2025Q2 | $1.16 | $2.02 | +73.9% |
| 2025Q1 | $-0.65 | $-3.42 | -426.6% |
| 2024Q4 | $2.06 | $1.90 | -7.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*